Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine ( PEI ) and a p53 gene administered in aerosol to treat established lung micrometastases as a model of human osteosarcoma in nude mice. The SAOS -LM6 cell line, a metastatic derivative of the p53 null SAOS -2 line, expresses high levels of p53 protein after in vitro transfection with PEI -p53 complexes as determined by ELISA, and transfection with both p53wt and the p53 variant, p53 -CD( 1 -366 ) in vitro, results in a marked inhibition of SAOS -LM6 cell proliferation. Aerosol delivery of plasmid DNA containing either the p53 gene or a p53 -CD( 1 -366 ) variant gene formulated with PEI to mice resulted in highly significant reductions in the numbers and size of tumors ( P < .001 ), the total number of tumor foci in the lungs ( P < .001 ) and the size of individual tumor nodules in treated animals compared to untreated, PEI only -treated and PEI -CAT -treated control animals. The different tissues examined did not reveal any signs of toxicity or inflammation after repeated exposure to PEI -DNA. The aerosol delivery of PEI -based formulations of p53 or synthetic p53 variant genes represents a promising new strategy for the treatment of established human osteosarcoma lung metastases. The noninvasive nature of aerosol delivery coupled with low toxicity also make this therapeutic approach potentially appropriate for combination therapy with either radio -or chemotherapy.
I
nactivation of p53wt, a tumor suppressor gene, has been observed in a majority of small cell and nonsmall cell lung cancers. 1, 2 Other tumors that frequently metastasize to lung, such as colon, breast, liver, and bone also exhibit a high incidence of p53 mutations and deletions. Greater than 30% of patients with osteosarcoma, the most common primary malignant bone tumor, develop lung metastases despite aggressive combination chemotherapy and surgery. Several studies have suggested that gene replacement therapy with p53wt results in an antitumor response that may be of therapeutic value in this situation. 3 -7 Until recently, a reproducible osteosarcoma lung metastasis model has not been available. An athymic nude mouse model of human osteosarcoma lung metastases ( SAOS -LM6) has now been developed by repeated cycling of SAOS-2 tumor cells in mice, 8 and appears to be suitable for evaluation of both chemotherapeutic 9 and gene therapeutic 10 approaches for treatment of this disease.
SAOS -2, the parent line from which SAOS -LM6 cells were derived, is null for p53 and transfection with p53wt has been shown to be associated with terminal differentiation and apoptosis that inhibit progressive growth of metastasis. 11 In addition, induction of p53 in SAOS -2 cells stably transfected with p53wt under the tight control of a tetracycline promoter resulted in an increased sensitivity to cisplatin cytotoxicity 12 and others have found that p53 transfection of SAOS-2 cells resulted in increased radiosensitivity. 13 SAOS-LM6 cells also lack p53 and when transfected in vitro by either p53wt or p53CD( 1-366 ), a functional p53 deletion variant, cell proliferation is significantly inhibited. We were interested in testing p53CD( 1 -366 ) because our unpublished data (Fung et al ) showed that this truncated variant may have better transcriptional activation and growth suppression ability than p53wt in cells at the G 0 /G 1 phase of the cell cycle.
Gene therapy of tumors with tumor suppressor genes has employed several approaches, including intravenous (i.v. ) administration of the genes delivered with viral or nonviral vectors. Immune responses and possible pathologic consequences associated with viral vectors remain a concern for human clinical applications, especially when repeated treatments may be necessary. Nonviral vectors, though generally less efficient than viral vectors, offer some advantages, and in vivo transfection efficiency has improved in recent years. Intravenous approaches using cationic lipid vectors have received some attention for the treatment of cancer 5 and intrapulmonary approaches such as intratracheal instillation have also resulted in some success of antitumor gene therapy in animal models. 6 However, such an approach would have technical limitations for use in human patients and, moreover, does not effectively reach the more peripheral regions of the lungs. We have previously found that polyethyleneimine:DNA (PEI -DNA ) complexes are stable during the process of jet nebulization and deposit uniformly throughout the lung. We have recently shown that aerosol delivery of PEI -DNA complexes results in significant levels of gene expression in the lungs of mice, 14, 15 and is associated with minimal inflammatory response. 15 Use of this technology produced substantial serum antibody responses to human growth hormone gene 14 and, in addition, produced significant antitumor effects in a mouse pulmonary model of murine melanoma. 7 For these reasons, we have chosen to examine the effect of p53 and p53CD( 1 -366 ) gene therapy for treating human osteosarcoma lung metastases in the SAOS -LM6 -nude mouse model using aerosol PEI -p53 delivery.
MATERIALS AND METHODS

Animals
Four to six -week -old specific -pathogen -free athymic male nude mice were purchased from Charles River Breeding Laboratories (Kingston, MA ). Tumors were implanted at M. D. Anderson Cancer Center and the mice were kept there until treatments were initiated at Baylor College of Medicine. The facilities at both M. D. Anderson Cancer Center and Baylor College of Medicine are approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the Untied States Department of Agriculture, the Department of Health and Human Services, and The National Institutes of Health. Mice were housed five to a cage and kept in a laminar-flow cabinet under specific pathogen -free conditions for 2 weeks before use.
Plasmid DNA
Human wild -type p53 cDNA (pBSH19A ) 16 was subcloned into pET8C and the resulting plasmid pETwt p53 was used as a template for the construction of pETp53CD( 1-366 ) by PCR. The plasmids were then transferred to pCMV-neoBam, placing the p53 gene under the control of the human cytomegalovirus promoter /enhancer element. The plasmid ( p4119 ) used as a control contains the bacterial chloramphenicol acetyl transferase (CAT ) gene under the control of the cytomegalovirus ( CMV ) promoter /enhancer element. The plasmids were purified commercially by Bayou Biolabs ( Harahan, LA ), were endotoxin free and were quantitated using UV absorbance. Agarose gel analysis revealed the plasmids to be primarily in the supercoiled form with a small amount of nicked plasmid.
PEI -DNA formulations
PEI (25 kDa, branched form ) was obtained from Aldrich Chemical ( Milwaukee, WI ). A stock solution of PEI was prepared at a concentration of 4.3 mg /mL (0.1 M in nitrogen ) in water. DNA contains 3 nmol of phosphate per microgram and appropriate concentrations were prepared in water. The desired amount of DNA in PBS was complexed with PEI by slowly adding the DNA to the PEI while vigorously vortexing the solution. The solution was then allowed to incubate at room temperature for 15-20 minutes before use. The resulting charge ratio is expressed as PEI nitrogen:DNA phosphorous (N:P) based on the composition of PEI with 581 mol of nitrogen per mole, and DNA with 3 nmol of phosphate per microgram. At a 10:1 N:P ratio, a 1.29:1 PEI:DNA weight ratio would be used.
Human osteogenic sarcoma cell line
SAOS-LM6 is a cell line derived from human osteosarcoma ( SAOS -2 ) cells by repeated cycling of tumor cells in mice. 8 It has been shown to form tumors in the lung following i.v. injection where microscopic pulmonary metastases are evident by 5 to 6 weeks with macroscopic disease present by 8 weeks.
Tissue culture for in vitro studies
The SAOS -LM6 cell line was derived as previously described. 8 Cells were cultured in Eagle's minimal essential medium (EMEM) supplemented with 10% heat -inactivated (568 for 30 minutes ) fetal bovine serum ( FBS ), 2 mM Lglutamine, 1ÂNEAA, 1 mM sodium pyruvate, 2Â vitamins and 50 g /mL gentamicin. Cells were incubated in a cell culture incubator at 378C and in the presence of 5% CO 2 . Only cells younger than 12 weeks after thawing from liquid nitrogen were used for in vitro study.
In vitro transfection
For serum -free transfections, cells were plated at 1.5Â10 5 cells/ well in 12 -well plates the day before transfection, though some loss of cells was apparent after plating. Cells were approximately 80% confluent at the time of transfection. After PEI -DNA complexing was complete (see above), the PEI -DNA formulations were brought up in EMEM supplemented with 10% FBS as above to a final DNA concentration of 1 g/mL. Cells were overlaid with the 1 mL of the transfection solution per well ( three wells were generally transfected for each time point or condition ). Plasmid -PEI complexes were prepared at a nitrogen to phosphate ( N:P ) ratio of 10:1. After 24 hours the transfection solution was removed, the cells were rinsed two times with PBS and overlaid with EMEM supplemented with 10% FBS. At various time points, cells were either rinsed twice with PBS and lysed using a lysis buffer ( 0.1 M TrisHCl, 0.5% Triton X -100 (Sigma, St. Louis, MO ), and assayed for transgene ( p53) expression or were trypsinized and counted to determine proliferation rates.
In vivo transfection with PEI -DNA by aerosol PEI -DNA formulations were prepared as described above except that the concentration of DNA was decreased to 2 mg per 10 mL ( after addition of the appropriate concentration of PEI ) by dilution with WFI water for one nebulizer dose. The Aerotech II nebulizer was run at a flow rate of 10 L / minute. The aerosol from the nebulizer was passed through a sealed plastic cage (13Â17Â30 cm ) that housed the mice. Air exited this chamber through a HEPA filter and the entire apparatus was situated under a laminar -flow hood vented through additional HEPA filtration. The mice were treated with PEI -p53 complexes twice a week for 4 weeks, starting 6 weeks after inoculation of the cancer cells into the mice. Control groups included untreated mice, mice treated with PEI or with PEI -CAT complexes. Dosage was 2 mg plasmid ( in 10 mL of aerosolized solution ) at a PEI -DNA ( N:P ) ratio of 10:1. Aerosol was delivered using 5% CO 2 in air as described previously by this laboratory. 15 The exposure required approximately 30 minutes, during which time the mice were allowed to move freely about the chamber.
Development of lung micrometastases
Before being inoculated, the SAOS -LM6 cells were harvested in midlog phase of growth by trypsinization using 0.25% trypsin /0.02% EDTA (wt /vol ). The cells were suspended in supplemental EMEM and pipetted so as to produce a single -cell suspension. The cells were then washed and resuspended in Ca 2 + -and Mg 2 + -free HBSS at 5Â10 6 cells /mL. Single -cell suspensions of 1Â10 6 cells / 0.2 mL were injected into the lateral tail vein of nude mice by using a 30-G needle with a 1 -mL disposable syringe. Cell viability was > 95% before injection and > 88% after the injection process was completed as assessed by trypan blue exclusion. The mice were evaluated daily for emaciation, lethargy, or other evidence of incapacitation. cells/ well in a 48-well plate ) were transfected with PEI -DNA complexes for 24 hours. The cultures were then washed and cells lysed using cell lysis buffer. After centrifugation, 100 l of the lysate was used for p53 ELISA. The p53 levels were normalized to the total protein content measured by the BCA protein assay (Pierce, Rockford, IL ). For in vivo expression, athymic nude mice were exposed to PEI -p53 aerosol, sacrificed at various time points (24, 48, 72 , and 96 hours ) later, and the lungs harvested and weighed. The lungs were homogenized in 1 mL of ice -cold cell lysis buffer ( 20 mM Tris, 0.5 mM EDTA, 1% Nonidet P40, 0.05% sodium dodecyl sulfate (SDS ), 1 mM PMSF, 1 mg /mL pepstatin, 2 mg /mL leupeptin ) using a Wig -L -Bug bead homogenizer (Crescent, Lyons, IL). After centrifugation at 48C, 100 l of the supernatant was used for p53 ELISA performed in a 96 -well plate. The absorbance ( 450 nm ) was read in triplicate using a Molecular Devices ( Sunnyvale, CA ) microtiter plate reader. The amount of p53 was determined using a standard curve prepared with purified p53. The assay can detect p53 levels as low as 10 pg /mL and the linear measuring range of the assay is 50-1000 pg /mL. The total protein content in the lungs was determined using the BCA protein assay.
Evaluation of tumor burden
Mice were sacrificed on week 12 in the first study and on week 13 in the second study after inoculation with cancer. The lungs were resected, weighed, fixed in Fekets solution ( 90% ethanol, 5% acetic acid, 5% formaldehyde ) and examined under a dissection microscope to count the visible foci. The growth of tumor contiguous to the lung was DENSMORE, KLEINERMAN, GAUTAM, ET AL: AEROSOL CANCER GENE THERAPY considered as a part of the lung for weighing the lungs. Tumor index was calculated by taking into account the lung weights, size of tumor foci, and the number of tumor foci.
p53 immunohistochemistry
PEI -p53CD1 DNA complexes were prepared at an N:P ratio of 10:1 at a DNA concentration of 2 mg /10 mL, and a total of 4 mg DNA was aerosolized to the mice. Twenty-four hours after aerosol delivery, the mice were sacrificed and the lungs were isolated, cannulated, and fixed by inflation with 50% (vol / vol ) OCT ( optimal cutting compound, Sakura Finetek, Torrance, CA ) in saline. Cryosections were cut at 5 m, collected on slides, air dried and incubated with 0.6% H 2 O 2 for 20 minutes to inactivate endogenous peroxidase activity. The slides were blocked using 20% normal goat serum for 30 minutes at room temperature (RT ). The slides were then incubated with a rabbit polyclonal antibody to p53 ( 1:200 dilution; Novocastra, Newcastle upon Tyne, UK ) for 1 hour at RT. After washing with PBS, the sections were incubated with a peroxidase conjugated goat antirabbit IgG ( 1:1000 dilution; Cappel, Westchester, PA ) for 1 hour at RT. The slides were then developed using aminoethylcarbazol ( AEC ) for 3 -5 minutes. Slides where the primary antibody was excluded were used as controls. Lungs from naive mice were also used as controls.
Toxicity analysis
In addition to the mice injected with SAOS -LM6 cells, three mice not injected with cancer cells were included in each of the treatment groups to detect any pulmonary inflammation or other signs of toxicity. After the therapy was terminated, the mice were anaesthetized with isoflurane and sacrificed by exsanguination via the abdominal aorta. Lungs were isolated, cannulated, and fixed by inflation with 10% neutral buffered formalin, embedded in paraffin and processed for histological analysis. Other tissues such as liver, kidney, spleen, brain, and heart were also isolated and fixed in 10% NBF. Thin sections were cut at 4 m and observed under the microscope to look for any signs of inflammation or toxicity using the hematoxylin and eosin stain. In addition, both animals and lungs were weighed and compared to untreated controls for any signs of emaciation or toxicity due to the treatment.
Statistics
After performing one-way analysis of variance ( ANOVA ) to compare the means, comparisons among groups were made using the two -tailed, unpaired Student's t test. A difference was considered significant at P .05. Figure 2 . p53 expression in the lungs of athymic nude mice after PEI -p53 aerosol delivery. Two milligrams of p53 plasmid was complexed to PEI ( N:P ratio of 10:1 ) and aerosolized to mice ( n = 5 per group for a total of 20 animals exposed simultaneously ). ''Control'' animals ( n = 5 ) were not exposed to aerosol. The mice were sacrificed after 24, 48, 72, and 96 hours, the lungs harvested and assayed for p53 expression in triplicate. Values are mean ± SD ( picograms per milligram protein ). Figure 3 . Immunohistochemistry of p53 expression in lungs after PEI -p53 aerosol delivery. Two milligrams of p53 plasmid was complexed to PEI ( N:P ratio of 10:1 ) and aerosolized to mice ( B ). ''Control'' animals ( A ) were not exposed to aerosol. The mice were sacrificed after 24 hours, the lungs harvested and were isolated, cannulated and fixed by inflation as described in the Materials and Methods section. Both treated and control tissues were simultaneously processed for p53 immunohistochemistry. For contrast, the control lung sections were stained with methyl green after the immunohistochemical staining.
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RESULTS
Transfection of SAOS -LM6 cells in vitro by PEI -p53 complexes
ELISA assay revealed that transfection of SAOS -LM6 cells produced a 24 -fold increase in the levels of p53 protein measured at 24 hours above that detected in parental ( nontransfected ) cells (Table 1 ) . There was also a reduction in the proliferation of SAOS -LM6 cells transfected in vitro with p53 or with p53CD( 1 -366) compared to cells transfected with PEI complexed to the control plasmid, NeoBam ( Fig 1 ) . While transfection with the control formulation resulted in some cytotoxicity in this cell line, the cells transfected with the PEI -NeoBam control exhibited a DENSMORE, KLEINERMAN, GAUTAM, ET AL: AEROSOL CANCER GENE THERAPY continued recovery of cell growth starting 3 days after transfection whereas the PEI -p53 and PEI -p53CD( 1 -366 ) treated cells did not exhibit signs of recovery until a week after transfection.
p53 expression in mouse lung following aerosol delivery of PEI -p53 complexes Two milligrams of p53 was complexed with PEI at a PEI:DNA (N:P) ratio of 10:1 and aerosolized to athymic nude mice ( the same strain used in the tumor studies described below ). p53 expression in lung was analyzed by ELISA at different time points ( 24, 48, 72 , and 96 hours ) after aerosol delivery of the PEI -p53 complexes to the mice ( Fig 2) . Aerosol delivery of PEI -p53 complexes lead to about a 3-fold increase in the levels of p53 detected in the lung tissue compared to that detected in the lungs of naive mice. In contrast to the persistence of reporter gene expression observed after 1 month when PEI -CAT is delivered by aerosol, 18 p53 expression in whole lung subsided faster, dropping to background levels after 3 days. For this reason, an aerosol treatment frequency of two treatments per week was chosen for the in vivo tumor suppression studies. PCR data from the same tissues complimented the ELISA data regarding the persistence of p53wt message (data not shown ). Immunohistochemical staining for p53 expression performed on frozen sections of lungs 24 hours after aerosol delivery of PEI -p53CD( 1 -366 ) is shown in Figure 3 . Immunohistochemistry for p53CD1 reveals that mainly the epithelial cells lining the conducting airways were transfected by the PEI -p53CD1 complexes with no staining being observed in the control lungs. Nearly all the conducting airways, including the terminal airways, and large airways were intensely stained for the p53CD1 protein. There was a diffuse staining of the alveolar lining cells, with intense staining in some individual cells. This is similar to the expression of aerosol-delivered PEI -CAT. 18 Suppression of SAOS -LM6 lung metastases by aerosol delivery of PEI -p53 and PEI -p53CD( 1 -366 ) Suppression of established osteosarcoma micrometastases in lung is of great concern in clinical settings. Here we tested the efficacy of aerosol delivery of PEI -based formulations of both p53 and the functional variant p53CD( 1-366 ) for suppression of SAOS -LM6 in athymic nude mice. Athymic nude mice were injected with 1Â10 6 SAOS -LM6 cells on day 0. Micrometastases were allowed to develop for 52 days before intiating aerosol treatment. Treatment was twice weekly for 5 weeks ( 10 treatments ). On day 88 post tumor inoculation ( 1 day after the final aerosol treatment ), the mice were sacrificed and the lungs fixed and tumor index was calculated. These same tissues were later paraffin embedded and sectioned for quantification of internal micrometastases. The mice treated with PEI -p53 and PEI -p53CD( 1-366 ) had a very low tumor index (P < .0001 and P < .0001 ) (Fig 4,  A and B ) . A majority of untreated mice or mice treated with PEI alone had numerous (often uncountable ) tumor nodules. The average size of tumors in these control animals was significantly larger than tumors, when present, in p53 or
p53CD( 1-366 ). A nearly identical experiment was run wherein animals injected with 1Â10
6 cells were treated beginning on day 56 for 29 days (nine treatments ). Animals were sacrificed 1 week after the last aerosol treatment. In this experiment, an additional nonspecific control group consisting of PEI -CAT was used and again p53wt resulted in significantly lower tumor index than untreated, PEI alone, or PEI -CAT groups ( Fig 5 ) , confirming the results shown above and providing evidence that the tumor-suppressive effect of p53 and p53CD( 1 -366) is specific.
Toxicity associated with aerosol PEI -DNA therapy
There were no signs of acute inflammatory responses, including neutrophil infiltration or tissue damage, in any of the tissues examined from any of the treatment groups. In addition, there was no significant loss of body weight of p53 or p53CD( 1 -366 ) treated animals over the period of treatment when compared to the untreated, nontumorbearing control animals (data not shown ). However, tumor-bearing animals treated with PEI or PEI -CAT showed a significant loss of weight, similar to untreated tumor-bearing animals.
DISCUSSION
We have shown that PEI -DNA gene aerosol formulations are resistant to the shear forces of nebulization, a problem associated with many cationic lipid -based gene formulations 17 and, as a result, levels of expression were sufficient to result in a meaningful immune responses to the human growth hormone gene delivered in PEI -gene aerosol. Tumor Index Figure 5 . Suppression of SAOS -LM6 lung metastases by PEI -p53 and PEI -CAT aerosol delivery. Mice were injected via lateral tail vein with 25,000 B16 -F10 cells on day 0. The mice were then either not treated or treated with PEI alone, PEI -p53 or PEI -CAT aerosol complexes twice a week ( Monday and Thursday ) starting on day 56. The last treatment was on day 87 post tumor cell injection, for a total of 10 aerosol exposures. The mice were sacrificed on day 88, the lungs harvested, weighed, and fixed in Fekets solution. Tumor index was calculated by the formula: tumor index = lung weightsÂnumber of fociÂsize of foci. Values are the mean ± SD ( n = 10 mice per group ). PEI -CAT aerosol delivery did lead to significant tumor reduction compared to the untreated or PEI -treated tumor -bearing animals ( P < .05 ). PEI -p53 in this experiment led to a highly significant antitumor effect compared to all other groups ( P < .001 ).
Recently, additional modifications of the aerosol delivery process by the use of 5% CO 2 in the generation of aerosol have resulted in further enhancement of gene expression in lung. 15 The efficiency of expression of aerosol-delivered p53 and p53CD( 1 -366) in airway epithelial cells is nearly 100% with evidence of staining in alveolar cells. A detailed description of the deposition of aerosolized PEI and transgene expression in the lungs is described elsewhere. 18 Anticancer studies reported here showed that aerosol delivery of p53wt and the synthetic p53 variant CD -1 caused a significant reduction in lung metastases in a nude mouse model of osteosarcoma. The lung weights and tumor burden for the p53-treated groups were significantly reduced when compared to untreated mice as well as to mice treated with PEI alone or with PEI -pCMVCAT. Although the PEI -CAT aerosol delivery did lead to significant tumor reduction compared to the untreated or PEI -treated tumor-bearing animals in one of the experiments, the PEI -p53 in this experiment led to a highly significant antitumor effect compared to all other groups, including PEI -CAT. The reason for the PEI -CAT-mediated antitumor effect is unknown. One possibility is because of the long -term expression of CAT (about a month ), which could have some growth inhibitory effect. 18 In addition to the results achieved here with p53 and the nude mouse osteosarcoma lung metastases model, we have also shown previously that aerosolized PEI formulations of p53 results in a significant antitumor response and extended survival in a murine melanoma ( B16 -F10 melanoma in C57 BL / 6 mice) model. 7 These two models differ considerably. The melanoma is a more aggressive tumor and the treatments were initiated only 1 day after animals were injected i.v. with cells ( inhibition of metastasis ), whereas the treatment of the SAOS -LM6 model, which had been i.v. injected with cells 6 -8 weeks earlier in this study resulted in the reduction / inhibition of growth of established micrometastases. The host C57 BL / 6 mice used in those earlier studies were not immune deficient, yet treatment with control plasmids, such as a luciferase, resulted in no inhibition of tumor growth in vivo, indicating that p53 antitumor effect in that model was not likely to be the result of a CpG immunostimulatory response or other immune response. We have since shown that aerosol delivery of PEI -DNA formulations results in a dramatic reduction in the cytokine response when compared to other delivery vectors and modes of delivery. 19 This lack of a CpG effect may help to explain why we have found that repeated aerosol exposures to PEI -DNA result in a sustained transgene expression in the lungs over a period of time. 18 The significant antitumor response against SAOS -LM6 tumors in nude mice, which exhibit a reduced immune response, is further evidence of a specific p53 antitumor effect.
Aerosol PEI -p53 treatment resulted in a significant increase in the length of survival in mice injected with B16 -F10 cells when compared to controls. 7 We now want to determine survival time of mice with SAOS -LM6 tumors treated with p53 and p53 variant genes by this approach. Due to the much longer survival time of untreated SAOS -LM6 nude mice ( > 6 months for SAOS -LM6 vs. approximately 28 days for B16 -F10 melanoma in C57 BL /6 mice ), changes in survival time in this model may be more predictive of clinical success in human disease.
The possible mechanisms by which the p53wt gene might be having a tumor-suppressive effect have been discussed elsewhere. 7 Expression of p53wt in the human osteosarcoma line SAOS -2, the parent line of SAOS -LM6, has been shown to induce apoptosis leading to cell death. 20 These workers also showed that this cell death was significantly reduced in a SAOS-2 variants that express high levels of the Bcl -2 suppressor of apoptosis. Similarly, expression of p53wt in SAOS -LM2, another metastatic variant line of SAOS-2, was shown to be associated with terminal differentiation and apoptosis that inhibits progressive growth of metastases. 11 In addition, current investigations in our laboratory of the antitumor mechanisms of aerosol-delivered p53 in our models suggest that the effect could be mediated through antiangiogenic factors up-regulated by p53 transfection ( Gautam et al, unpublished ) .
In addition to wtp53, we also tested a truncated p53, p53CD( 1-366 ). Our unpublished data (Fung et al ) showed that p53CD( 1 -366) may have better transcriptional activation and growth suppression ability compared to p53wt in cells at the G 0 /G 1 phase of the cell cycle. This is consistent with prior observations that contact-inhibited cells lack p53 transactivation ability, which can be overcome by stimulating the cells to enter the cell cycle by overexpression of cyclin E. 21 This is due to the fact that wild -type p53 can assume two different conformations. Newly synthesized p53 in a cell exists in an inactive conformation and must be activated by posttranslational modification during S phase. In its inactive conformation, p53wt cannot bind DNA and cannot transactivate. The active conformation of p53 also exists in cells by differential splicing under certain conditions, e.g., during the G2 /M phase of the cell cycle or when cells are exposed to stress. P53CD( 1-366 ) mimics this conformation and can bind specific DNA sequences and is transcriptionally active at all phases of the cell cycle. The significant effect of p53CD( 1-366) on tumor growth is promising and the differences between the levels of inhibition achieved with the variant versus the wild -type p53 genes may be attributable to experimental variability. Based on in vitro cell proliferation studies with a number of tumor cell lines that have consistently shown the p53CD( 1-366 ) variant to be more effective than the wild -type gene in arresting the growth of cells ( data not shown ), one might suspect the in vivo tumor-suppressive effect of p53CD( 1-366 ) to be equal or better than that of the wild -type gene. In fact, the p53CD( 1-366) variant did result in a higher level of tumor suppression in studies involving the C57 BL /6 mice (Gautam et al, unpublished ) and further studies with this and other p53 variants are underway.
Similarly, expression of the tumor suppressor retinoblastoma (RB ) gene in SAOS -2 cells, which have been shown to have a defect in this gene, also reportedly results in suppression of tumor growth. 22, 23 However, some of this work suggests that RB and p53 play different roles in carcinogenesis of osteoblasts with RB inactivation releasing cells from G 0 /G 1 arrest and suppresses cell differentiation whereas p53 inactivation enhances cell proliferation by repressing both apoptosis and cell cycle arrest at G 0 /G 1 and G 2 /M. Although there is evidence that RB is not always necessary for induction of G 1 arrest by p53, one of the pathways for p53 is considered to be regulation of RB phosphorylation through the induction of a cyclin -CDK inhibitor p21WAF1 /C1P1. 23 -25 We are currently evaluating the tumor-suppressive effects of aerosol-delivered PEI -RB formulations in several animals tumor models. We are also evaluating the possible synergistic effects of delivering PEIbased formulations of both p53 and RB using this model.
The lack of acute toxicity or an inflammatory response in animals treated repeatedly with aerosol PEI -p53 or PEIp53CD( 1-366) for many weeks is also an important finding. We saw no difference in the weights of nontumorbearing animals that were treated repeatedly or not treated during the study. In addition, there were no significant differences in weights between nontumor animals and tumor-bearing animals treated with PEI -p53 or PEIp53CD( 1-366), providing additional evidence of the relative health of the animals undergoing long -term aerosol PEI treatment. This is in agreement with our previous reports of the lack of an acute inflammatory response 15 and a reduction in pulmonary cytokine response 19 after short -term aerosol exposure to PEI -DNA formulations when compared to other delivery vectors or modes of plasmid DNA delivery.
The significant tumor-suppressive effects of aerosoldelivered PEI -p53 constructs may hold even greater promise for patients with osteocarcinoma when one considers that the stable expression of p53 in p53 null SAOS -2 cells results in both a significant increase in in vitro radiosensitivity 26 and a significant increase in in vitro sensitivity to the chemotherapeutic agent cisplatin. 12, 27 The noninvasive nature of inhalation therapy combined with the very low toxicity associated with the aerosol delivery of PEI formulations makes this therapeutic approach an excellent candidate for such combination therapy. Studies to determine the antitumor efficacy of aerosol PEI -p53 combined with the aerosol delivery of liposomal formulations of the chemotherapeutic agents paclitaxel and 9 -nitro -camptothecin, already shown to be effective against this model, 9 are currently underway.
